The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.00
Ask: 42.00
Change: -1.00 (-2.38%)
Spread: 2.00 (5.00%)
Open: 42.00
High: 42.00
Low: 41.00
Prev. Close: 42.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Gov Future Fund invests £360k in Nandi Proteins

16 Sep 2020 07:00

RNS Number : 0928Z
Frontier IP Group plc
16 September 2020
 

Reach

AIM: FIPP

16 September 2020

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - UK Government Future Fund invests £360,000 in Nandi Proteins as part of £720,000 fund raising

 

Frontier IP, a specialist in commercialising intellectual property, today notes the following announcement from portfolio company Nandi Proteins Limited ("Nandi" or the "Company") that it has raised £720,000 via a convertible loan, including a £360,000 investment from the UK Government's Future Fund.

 

The investment from the Future Fund, which was established to support innovative businesses through the COVID-19 outbreak, has been matched by £320,000 from the Group and £40,000 invested by Shackleton Finance Limited, which specialises in secondary venture and development capital investments. Frontier IP holds a 20.1 per cent equity stake in the Company. Shackleton is also an existing shareholder.

 

Nandi is collaborating with a number of industry partners to commercialise its novel process control technology to create ingredients based on animal and vegetable proteins able to replace chemical additives and fat in processed foods. The funding will support the Company in meeting technical and commercial milestones relating to a number of collaborative projects with major industry partners.

 

Frontier IP chief executive officer Neil Crabb said: "The investment from the Future Fund is an invaluable contribution to supporting Nandi Proteins through the next phase of its development. There is strong interest across the food industry to reduce the levels of additives, fats and meat on both health and environmental grounds. Nandi, with its proven expertise particularly with vegetable proteins, is well placed to benefit from these trends."

 

Nandi Proteins statement begins:

 

UK Government Future Fund invests £360,000 in Nandi Proteins as part of £720,000 fund raising

16 September 2020 Nandi Proteins Limited ("Nandi" or the "Company") today announces that it has successfully raised £720,000 via a convertible loan including £360,000 investment from the UK Government's Future Fund, established to support innovative businesses through the COVID-19 outbreak.

The Future Fund's investment has been matched by Frontier IP Group, a specialist in commercialising intellectual property, and Shackleton Finance Limited, a technology-focused venture capital manager. They have invested £320,000 and £40,000 respectively.

The convertible loan will enable Nandi Proteins to meet technical and commercial milestones for its novel process control technology. This is now at an advanced stage of commercialisation through collaborative partnerships with a number of major organisations.

 

Nandi's technology has a wide range of potential applications. It is based on the knowledge that the functional properties of proteins change as they denature when heat is applied in a very precise way over time. As a result, the technology is able to create new protein-based ingredients to replace chemical additives and fats in processed foods, such as meats, cakes and a host of other products.

Among other projects, Nandi is leading a consortium developing gluten replacements for use in bread. Other members of the consortium include global ingredients business AB Mauri, part of FTSE 100 group AB Foods, and a major UK agronomy firm Agrii, a subsidiary of agri-services group Origin Enterprises. The project is backed by a grant from Coeliac UK and Innovate UK.

The Company is a spin out from Heriot-Watt University, Edinburgh. More information on the principles underpinning Nandi's technology is below.

Nandi Proteins chairman John Price said : "I have been very impressed with the progress at Nandi Proteins since becoming chairman late last year, reflected in the range and strength of the industry collaborations it has been able to forge. We are confident that the Company will see the significant momentum generated to date accelerate as the results of our industry collaborations start to come through."

Nandi Proteins Acting Chief Executive Officer and Frontier IP Chief Commercialisation Officer Matthew White said: "Nandi Proteins is addressing many of the food industry's major concerns including the dangers of obesity, a problem thrown into greater focus by the impact of COVID-19. We are very much looking forward to continuing our work with both existing and new industry partners as they seek to tackle these issues."

 

 

Nandi: the technology

Nandi's patented technology is based on the knowledge that the functional properties of proteins change when they unfold (denature). Controlled denaturation can be used to deliberately change and control the protein functionality as an ingredient. The Company is focused on two protein types:

 

· globular proteins, where the molecules are folded into a spherical shape, found in vegetables and dairy; and

· spiral proteins, where long chains of molecules form spirals or helices. They are found in meat.

In both cases, chemical bonds along the length of, and between different portions of, the protein molecule keep the proteins in their shapes.

 

Applying heat breaks the weak bonds allowing the proteins to unfold. The structure of the protein that was previously 'inside' the folded protein is now exposed. This allows it to interact with its surroundings -- for example by binding onto water molecules -- enhancing functionality such as solubility and emulsifying ability.

 

The unfolded structure also allows for new chemical bonds to form between one protein to another. The result is that individual protein molecules can become joined together to create a network which will change functional properties such as thickening and gelation abilities.

 

These denaturation processes are already widely used in food ingredient processing and cooking. For example, an egg white consists of globular proteins suspended in water. When you fry the egg, the proteins unfold and create a mesh, which traps the water molecules. The egg white solidifies. The challenge is in controlling the process precisely. Cook the egg for too long, too many protein bonds form, the net's mesh becomes too tight, and the white becomes rubbery.

 

By controlling the heat applied and monitoring the unfolding process extremely precisely, Nandi can precisely create protein functionality that allows it to replace the functionality of fat and additive molecules such as emulsifiers.

 

Nandi is capable of producing modified proteins from both globular proteins (present in a wide range of naturally-occurring foodstuffs, including whey, potato, soy and peas, as well as eggs) and spiral proteins present in meat (Nandi is specifically exploring the modification of collagen proteins).

 

Nandi achieves control of the unfolding process by using chemistry and light-based systems to measure in real time a range of key variables as heat is applied to proteins in solution. This allows the Company to maximise their functional properties, such as emulsification, solubility, acid stability, foaming, water binding and gelation.

 

The company's technology includes proprietary sensor systems which can be used across existing manufacturing processes to control the variables and create functional proteins.

 

Nandi Proteins statement ends

 

 

ENQUIRIES

 

Frontier IP Group plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / James Hornigold

 

 

 

 

 

 

 

 

 

ABout frontier IP

The Group's convertible loan to Nandi Proteins was made by Frontier IP Management Limited, a wholly-owned subsidiary and an Appointed Representative of Privium Fund Management (UK) Limited ("Privium") which is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom.

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAMZGMLNKVGGZM
Date   Source Headline
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.